Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 10/20 | 0.43 |
| ▸ | WNT1 | P04628 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 8/20 | 0.42 |
| ▸ | KDM1A | O60341 | 4/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CD38 | P28907 | 2/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22208414 | 0.86 | CNR2 (0.47) | DYRK1AWNT1RIPK1CNR1 | |
| SCHEMBL22208303 | 0.84 | RIPK1 (0.57) | DYRK1ARIPK1GSK3BKDM1ACNR1 | |
| SCHEMBL22208379 | 0.82 | DYRK1A (0.44) | DYRK1AWNT1RIPK1 | |
| SCHEMBL22208358 | 0.80 | CNR1 (0.41) | DYRK1AGSK3BKDM1AMAOBCNR1 | |
| SCHEMBL22208359 | 0.77 | FNTA (0.42) | RIPK1 | |
| SCHEMBL22208458 | 0.74 | RIPK1 (0.81) | DYRK1ARIPK1 | |
| SCHEMBL22208319 | 0.71 | KDM4E (0.37) | DYRK1A | |
| SCHEMBL22208399 | 0.68 | HTT (0.38) | DYRK1AWNT1 | |
| SCHEMBL24626551 | 0.68 | SMYD3 (0.48) | CNR1 | |
| SCHEMBL29675197 | 0.68 | SMYD3 (0.48) | CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421226-B2 | Heteroaryl compounds as necrosis inhibitors, composition and method using the same | ACCRO BIOSCIENCE (HK) LIMITED (HK) | 2025-09-23 | — | — | US | disclosed |
| US-20220112188-A1 | HETEROARYL COMPOUNDS AS NECROSIS INHIBITORS, COMPOSITION AND METHOD USING THE SAME | ACCRO BIOSCIENCE (HK) LIMITED (HK) | 2022-04-14 | — | — | US | disclosed |
| EP-3908277-A1 | HETEROARYL COMPOUNDS AS NECROSIS INHIBITORS, COMPOSITION AND METHOD USING THE SAME | Zhang, Xiaohu (CN) | 2021-11-17 | — | — | EP | disclosed |
| WO-2020146858-A1 | HETEROARYL COMPOUNDS AS NECROSIS INHIBITORS, COMPOSITION AND METHOD USING THE SAME | ACCRO BIOSCIENCE INC. (KY) | 2020-07-16 | — | — | WO | disclosed |
| WO-2020146858-A1 | HETEROARYL COMPOUNDS AS NECROSIS INHIBITORS, COMPOSITION AND METHOD USING THE SAME | ACCRO BIOSCIENCE INC. (KY) | 2020-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12421226-B2 | Heteroaryl compounds as necrosis inhibitors, composition and method using the same | TNF, LITAF, PNLIP | DYRK1A 4546/4885WNT1 4447/4885RIPK1 224/4885 |
| US-20220112188-A1 | HETEROARYL COMPOUNDS AS NECROSIS INHIBITORS, COMPOSITION AND METHOD USING THE SAME | TNF, LITAF, PNLIP | DYRK1A 4546/4885WNT1 4447/4885RIPK1 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.